Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Income from Continuing Operations (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Income from Continuing Operations for 16 consecutive years, with 1218000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 86.81% to 1218000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3198000.0 through Dec 2025, down 32.31% year-over-year, with the annual reading at 3196000.0 for FY2025, 32.23% down from the prior year.
  • Income from Continuing Operations hit 1218000.0 in Q4 2025 for Guided Therapeutics, down from 742000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 68000.0 in Q3 2021 to a low of 1807000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 768650.0 across 5 years, with a median of 693000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 84.68% in 2021 and later tumbled 1720.59% in 2022.
  • Year by year, Income from Continuing Operations stood at 444000.0 in 2021, then plummeted by 306.98% to 1807000.0 in 2022, then skyrocketed by 78.64% to 386000.0 in 2023, then tumbled by 68.91% to 652000.0 in 2024, then plummeted by 86.81% to 1218000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for GTHP at 1218000.0 in Q4 2025, 742000.0 in Q3 2025, and 811000.0 in Q2 2025.